clinical trial · NCT03178552
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche·phase3·active not recruiting·n = 1,000
Non-Small Cell Lung CancerAlectinibAtezolizumabPemetrexedCisplatinCarboplatinGemcitabineEntrectinibCobimetinib
brief summary
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.
started
Sep 22, 2017
primary completion
Oct 31, 2026
completion
Oct 31, 2026
last updated
Mar 9, 2026
official title
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol